Year None202120202019201820172016 August 13, 2021 Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights Go to August 4, 2021 Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021 Go to July 27, 2021 Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference Go to July 14, 2021 Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer Go to June 23, 2021 Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11 Go to May 28, 2021 Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights Go to Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last »
August 13, 2021 Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights Go to
August 4, 2021 Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021 Go to
July 27, 2021 Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference Go to
July 14, 2021 Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer Go to
June 23, 2021 Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11 Go to
